Protagonist Therapeutics, Inc. Forecast, price target & analysts
Protagonist Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Protagonist Therapeutics, Inc. Classifications & Recommendation:
Protagonist Therapeutics, Inc. Price Target
| Target Price | $71.40 |
| Price | $64.51 |
| Potential |
10.68%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Protagonist Therapeutics, Inc. 2026 .
The average Protagonist Therapeutics, Inc. target price is $71.40.
This is
10.68%
register free of charge
$86.10
33.47%
register free of charge
$47.47
26.41%
register free of charge
|
|
| A rating was issued by 18 analysts: 16 Analysts recommend Protagonist Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Protagonist Therapeutics, Inc. stock has an average upside potential 2026 of
10.68%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 434.43 | 46.68 |
| 624.05% | 89.26% | |
| EBITDA Margin | 58.87% | -313.10% |
| 139.10% | 631.87% | |
| Net Margin | 63.35% | -268.57% |
| 148.13% | 523.98% |
14 Analysts have issued a sales forecast Protagonist Therapeutics, Inc. 2025 . The average Protagonist Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Protagonist Therapeutics, Inc. EBITDA forecast 2025. The average Protagonist Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Protagonist Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Protagonist Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 4.23 | -2.02 |
| 404.32% | 147.75% | |
| P/E | negative | |
| EV/Sales | 73.75 |
14 Analysts have issued a Protagonist Therapeutics, Inc. forecast for earnings per share. The average Protagonist Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Protagonist Therapeutics, Inc....
Current Protagonist Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 19 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 17 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 17 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 19 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
